extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
1fec18d5fc
commit
92272eca05
5 changed files with 66 additions and 1 deletions
|
|
@ -54,6 +54,12 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0
|
|||
|
||||
Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon's 192K patient analysis adds cancer risk reduction to the multi-organ protection profile: ~50% lower ovarian cancer and 14% lower breast cancer in female users, plus associations with lower osteoporosis and rheumatoid arthritis rates. Adherent users (80%+) showed 47% MACE reduction for women and 26% for men, confirming cardiovascular benefits with sex-differential effects.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -59,6 +59,12 @@ The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2
|
|||
|
||||
The discontinuation problem is worse than just lost metabolic benefits - it creates a body composition trap. Patients who discontinue lose 15-40% of weight as lean mass during treatment, then regain weight preferentially as fat without muscle recovery. This means the most common outcome (discontinuation) leaves patients with WORSE body composition than baseline: same or higher fat, less muscle, higher disability risk. Weight cycling on GLP-1s is not neutral - it's actively harmful.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon data shows adherence is the binding variable for cost-effectiveness: benefits scale dramatically with 80%+ adherence, with diabetes patients showing 9 percentage points lower medical cost growth at 30 months (vs. 6 points for all users) and weight loss patients showing 7 points lower (vs. 3 points for all users). This quantifies the economic penalty of low persistence.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -43,6 +43,12 @@ The source does not provide granular income-stratified discontinuation rates, so
|
|||
|
||||
The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16*
|
||||
|
||||
Aon's commercial claims data (employer-sponsored insurance) shows strong benefits for adherent users, but the 192K sample represents healthier/wealthier employees with better coverage. The temporal cost pattern (costs up 23% year 1, then down to 2% growth year 2+) makes affordability barriers particularly damaging because patients who discontinue in year 1 bear costs without capturing savings.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,32 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
{
|
||||
"filename": "glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 2,
|
||||
"kept": 0,
|
||||
"fixed": 2,
|
||||
"rejected": 2,
|
||||
"fixes_applied": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-16",
|
||||
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor",
|
||||
"glp-1-receptor-agonists-show-50-percent-ovarian-cancer-reduction-and-14-percent-breast-cancer-reduction-in-female-users.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2026-01-13
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: report
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -49,3 +53,14 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im
|
|||
EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary.
|
||||
|
||||
flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"]
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Aon analyzed U.S. commercial health claims data from 192,000+ GLP-1 users in a multi-year study released January 13, 2026
|
||||
- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs. 10% for non-users
|
||||
- After 12 months: medical costs grow 2% vs. 6% for non-users
|
||||
- For diabetes indication: medical cost growth 6 percentage points lower at 30 months; 9 points lower with 80%+ adherence
|
||||
- For weight loss indication: cost growth 3 points lower at 18 months; 7 points lower with consistent use
|
||||
- Female GLP-1 users: ~50% lower incidence of ovarian cancer
|
||||
- Female GLP-1 users: 14% lower incidence of breast cancer
|
||||
- Adherent users (80%+): 47% MACE reduction for women, 26% for men
|
||||
|
|
|
|||
Loading…
Reference in a new issue